newsfilter
← Latest News
Business Wire·

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first and only HER2-directed medicine to improve progression-free survival over global standard of care in a Phase III trial in this setting Positive high-level results